The 2012 annual meeting of stockholders of Keryx Biopharmaceuticals, Inc. ("Keryx") was held on June 19, 2012. The following matters were voted on by the stockholders: the election of directors, the ratification of the appointment of UHY LLP as Keryx's independent registered public accounting firm for the year ending December 31, 2012, and the advisory vote on the compensation of named executive officers. At the meeting, Ron Bentsur, Kevin J. Cameron, Joseph Feczko, M.D., Wyche Fowler, Jr., Jack Kaye and Michael P. Tarnok were re-elected to the Board.

The vote with respect to each nominee is set forth below:

Nominee             Total Votes For Total Votes Withheld Broker Non-Votes
Ron Bentsur              10,895,108            3,824,635       37,918,482
Kevin J. Cameron         13,926,762              792,981       37,918,482
Joseph Feczko, M.D.      14,338,425              381,318       37,918,482
Wyche Fowler, Jr.        13,929,029              790,714       37,918,482
Jack Kaye                14,336,038              383,705       37,918,482
Michael P. Tarnok        13,946,192              773,551       37,918,482

The vote with respect to the ratification of the appointment of UHY LLP as Keryx's independent registered public accounting firm for the year ending December 31, 2012, is set forth below:

Total Votes For Total Votes Against Abstention Broker Non-Votes 51,910,811 529,771 197,643 0

The vote with respect to the advisory vote on the compensation of Keryx's named executive officers is set forth below:

Total Votes For Total Votes Against Abstention Broker Non-Votes 13,070,905 1,483,981 164,857 37,918,782

In accordance with the stockholders' recommendation at the 2011 annual meeting of stockholders held on June 21, 2011, Keryx has determined that an advisory vote on the compensation of the named executive officers of the Company will be conducted every year, until the next stockholder advisory vote is held on this matter.